Status:
COMPLETED
Altered Faecal Microbiome and Metabolome in CT1D, AT1D and T2D
Lead Sponsor:
Second Xiangya Hospital of Central South University
Conditions:
Type 1 Diabetes Mellitus Maturity Onset
Eligibility:
All Genders
5-70 years
Brief Summary
To elucidate the characteristics of global gut microbiota and fecal/serum metabolites in patients with childhood-onset type 1 diabetes, adult-onset type 1 diabetes or type 2 diabetes.
Detailed Description
Type 1 diabetes is caused by autoimmune destruction of pancreatic beta cells, leading to severe insulin deficiency and requiring insulin therapy. It is typically considered a disease of childhood and ...
Eligibility Criteria
Inclusion
- Diabetes diagnosed according to the report of WHO in 1999；
- Aged between 5 and 70 years old;
Exclusion
- Severe chronic cardiovascular or cerebrovascular disease；
- Severe abnormalities in liver or renal function;
- Hyperthyroidism; or other autoimmune diseases;
- Tumors, surgery or pregnancy;
- Treatments with oral hypoglycemic agents or immunomodulators;
- Subjects who had taken probiotics, prebiotics within one week or antibiotics within one month.
Key Trial Info
Start Date :
February 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 30 2022
Estimated Enrollment :
372 Patients enrolled
Trial Details
Trial ID
NCT05252728
Start Date
February 1 2019
End Date
April 30 2022
Last Update
July 11 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University
Changsha, Hunan, China, 410011